Bicara Therapeutics Inc (BCAX) PT Raised to $18 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts BCAX Hot Sheet
Price: $8.96 --0%
Rating Summary:
14 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 18 | New: 12
Rating Summary:
14 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 18 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Richard Law raised the price target on Bicara Therapeutics Inc (NASDAQ: BCAX) to $18.00 (from $16.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Goldman Sachs Downgrades Bicara Therapeutics Inc (BCAX) to Sell, 'Competitive Pressure In High Gear'
- Revvity Inc (RVTY) PT Raised to $160 at JPMorgan
- Muyuan Foods Co Ltd (002714:CH) PT Raised to RMB69 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
